以端粒酶为靶标抗癌药物筛选模型建立及端粒酶抑制剂筛选

新药研究与开发离不开筛选模型 ,而筛选模型的关键是寻找、确定和制备药物筛选靶———药靶 .近来研究表明 ,端粒酶与恶性肿瘤的发生和发展有着密切的关系 ,端粒酶在恶性肿瘤细胞中表达率占80 %～ 90 % ,而在正常体细胞中不表达1～ 4 ] .这表明端粒酶在维持肿瘤细胞的增殖中起着重要作用 .抑制端粒酶的活性有可能抑制肿瘤的生长 ,因而端粒酶被认为是恶性肿瘤诊断和治疗的新靶标 .以端粒酶为抗癌药物作用的靶标 ,建立抗癌药物筛选模型 ,在分子水平上筛选针对端粒酶的抑制剂 ,进而获得特异性高、针对性强、毒副作用小的新型广谱的抗癌药物 ,…

Determination of Telomerase from HeLa Cells as a Target for Screening Antitumor Agents

Telomerase, a ribonucleoprotein enzyme, has been found in immortalized but not in most somatic adult human tissues, and thus emerged as a novel target for cancer chemotherapy. Recently it has been found that telomerase is a fruitful target for oncologic drug development. A new method for screening antitumor agents by using telomerase as a target has been established according to the phenomena that the enzyme activity can be affected by some types of antitumor agents or chemicals. The telomerase was extracted from HeLa cells. The telomeric repeat amplification protocol(TRAP) was used to measure enzyme activity. Telomerase activity can be inhibited by 4 kinds of chemical compounds.